Showing results (31-40 of 181) with videos related to
Sort By:
Pageof 19
The Journal of Infectious Diseases|February 9, 2020
Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza SeasonMasatoki Sato, Emi Takashita, Masahiko Katayose, et al.Head & Neck|October 5, 2019
Long-term outcomes and toxicities of carbon-ion radiotherapy in malignant tumors of the sphenoid sinusYasuhito Hagiwara, Masashi Koto, Tapesh Bhattacharyya, et al.Therapeutic Drug Monitoring|November 19, 2016
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, et al.Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica|August 27, 2005
[A case of high FDG-uptake into the myocardium after radiotherapy for esophageal cancer]Keiichi Jingu, Kenji Nemoto, Tomohiro Kaneta, et al.Cancer Treatment Reviews|May 8, 2013
Management of high-risk prostate cancer: radiation therapy and hormonal therapyTakuma Nomiya, Hiroshi Tsuji, Shingo Toyama, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2008
Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised studyKatsuyuki Karasawa, Makoto Sunamura, Atsutake Okamoto, et al.Therapeutic Drug Monitoring|April 18, 2014
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophreniaAkifumi Nakamura, Kazuo Mihara, Kenji Nemoto, et al.Therapeutic Drug Monitoring|April 1, 2014
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophreniaTakeshi Suzuki, Kazuo Mihara, Akifumi Nakamura, et al.Neuropsychobiology|July 2, 2018
A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary StudyGoyo Nagai, Kazuo Mihara, Shoko Kagawa, et al.Therapeutic Drug Monitoring|January 28, 2020
A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related RashTakeshi Suzuki, Kazuo Mihara, Goyo Nagai, et al.Pageof 19